411 related articles for article (PubMed ID: 33202006)
1. Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
Bekerman E; Cox S; Babusis D; Campigotto F; Das M; Barouch DH; Cihlar T; Callebaut C
J Antimicrob Chemother; 2021 Feb; 76(3):692-698. PubMed ID: 33202006
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
[TBL] [Abstract][Full Text] [Related]
3. Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
Massud I; Ruone S; Zlotorzynska M; Haaland R; Mills P; Cong ME; Kelley K; Johnson R; Holder A; Dinh C; Khalil G; Pan Y; Kelley CF; Sanchez T; Heneine W; García-Lerma JG
EBioMedicine; 2020 Aug; 58():102894. PubMed ID: 32707451
[TBL] [Abstract][Full Text] [Related]
4. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
[TBL] [Abstract][Full Text] [Related]
5. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
[TBL] [Abstract][Full Text] [Related]
6. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
Robles G; Sauermilch D; Gandhi M; Starks TJ
AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
[TBL] [Abstract][Full Text] [Related]
7. Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
Mayer KH; Gelman M; Holmes J; Kraft J; Melbourne K; Mimiaga MJ
J Acquir Immune Defic Syndr; 2022 May; 90(1):27-32. PubMed ID: 34991141
[TBL] [Abstract][Full Text] [Related]
8. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
[TBL] [Abstract][Full Text] [Related]
9. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
[TBL] [Abstract][Full Text] [Related]
10. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
11. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
Herrera C; Serwanga J; Else L; Limakatso L; Opoka D; Ssemata AS; Pillay AD; Namubiru P; Seiphetlo TB; Odoch G; Mugaba S; Seatlholo P; Alieu A; Penchala SD; Muhumuza R; Alinde B; Petkov S; O'Hagan K; Callebaut C; Seeley J; Weiss H; Khoo S; Chiodi F; Gray CM; Kaleebu P; Webb EL; Martinson N; Fox J;
EBioMedicine; 2023 Jul; 93():104648. PubMed ID: 37327677
[TBL] [Abstract][Full Text] [Related]
12. Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection.
Massud I; Mitchell J; Babusis D; Deyounks F; Ray AS; Rooney JF; Heneine W; Miller MD; García-Lerma JG
J Infect Dis; 2016 Oct; 214(7):1058-62. PubMed ID: 27465645
[TBL] [Abstract][Full Text] [Related]
13. Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Dobard CW; Peet MM; Nishiura K; Holder A; Dinh C; Mitchell J; Khalil G; Pan Y; Singh ON; McCormick TJ; Agrahari V; Gupta P; Jonnalagadda S; Heneine W; Clark MR; García-Lerma JG; Doncel GF
EBioMedicine; 2022 Dec; 86():104361. PubMed ID: 36423375
[TBL] [Abstract][Full Text] [Related]
14. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
Stellbrink HJ; Lazzarin A; Woolley I; Llibre JM
HIV Med; 2020 Mar; 21 Suppl 1():3-16. PubMed ID: 32017355
[TBL] [Abstract][Full Text] [Related]
15. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
[TBL] [Abstract][Full Text] [Related]
16. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Spencer H; Bougatsos C; Blazina I; Ahmed A; Selph S
JAMA; 2023 Aug; 330(8):746-763. PubMed ID: 37606667
[TBL] [Abstract][Full Text] [Related]
17. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
DeKoven S; Naccarato M; Brumme CJ; Tan DHS
HIV Med; 2023 Nov; 24(11):1137-1143. PubMed ID: 37317505
[TBL] [Abstract][Full Text] [Related]
18. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
19. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
20. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
